Treg在大鼠重症肺炎克雷伯菌肺炎中的调控作用

doi:10.3969/j.issn.1000-8535.2015.05.001

广州医药 ›› 2015, Vol. 46 ›› Issue (5): 1-4.DOI: 10.3969/j.issn.1000-8535.2015.05.001

• 论著 • 下一篇

Treg在大鼠重症肺炎克雷伯菌肺炎中的调控作用

苏鸿, 赵子文, 钟维农, 魏树全, 赵祝香, 梁志科, 方昌全

广州医科大学附属广州市第一人民医院急诊科(广州 510180)

收稿日期:2015-04-15 发布日期:2021-11-30
通讯作者: 苏鸿,E-mail:subird704@126.com
基金资助:
广州市医药卫生科技项目(20131A011020)

Role of Treg in the mouse severe Klebsiella pneumonia

Su Hong, Zhao Ziwen, Zhong Weinong, et al

Department of Emergency,Guangzhou First People's Hospital, Guangzhou Medical University, Guangzhou 510180, China

Received:2015-04-15 Published:2021-11-30

摘要/Abstract

摘要： 目的确定CD4⁺CD25⁺Treg调节性T细胞在重症肺炎克雷伯菌肺炎中的表达以及意义,探讨CD4⁺CD25⁺Treg在重症肺炎克雷伯菌肺炎的免疫抑制中的调控作用。方法通过气管内滴注肺炎克雷伯菌菌液建立重症肺炎模型。采用流式细胞仪检测CD4⁺CD25⁺Treg细胞及酶联免疫吸附法(ELISA)等方法检测各种细胞因子。结果重症肺炎克雷伯菌肺炎大鼠的脾脏和肺中CD4⁺CD25⁺Treg的数量增加。使用了CD25抗体(PC61)去除机体内源性的CD4⁺CD25⁺Treg,分别去除脾脏和肺的94%和90%的CD4⁺CD25⁺Treg。CD25抗体组在建模4 h,12 h及24 h后,肺部MPO及血清IL-1,IL-6,MIP-2较对照组高(P<0.05),肺和BLA比对照组高(P<0.05),CD25抗体组大鼠生存率比对照组低(P<0.05)。结论内源的CD4⁺CD25⁺Treg对大鼠抑制重症肺炎克雷伯菌肺炎的过度免疫损害反应起到保护作用。

关键词: 调节性T淋巴细胞, 肺炎, 脓毒症, 肺炎克雷伯菌

Abstract: Objective To confirm the expression and meaning of the T regular cell in the severe Klebsiella pneumonia, and to evaluate the regular and control affect in the immunologic suppression of the severe Klebsiella pneumonia. Methods To build the severe pneumonia model by intratracheally inoculated with Klebsiella pneumoniae bacteria. To check sorts of inflammation factors by the methods of ELISA and flow cytometry. Results The quantity of the CD4⁺CD25⁺Treg in the splenic and lungs of the mice with severe Klebsiella pneumonia were increased. Anti-CD25Ab(PC61) was used to remove endogenousCD4⁺CD25⁺Treg. Anti-CD25 treatment remove 90% of CD4⁺CD25⁺Treg cells. The cytokine production(IL-1β,IL-6,MIP-2)in the anti-CD25-treated group were significantly increased. And it also increased significantly in the airway neutrophil infiltration, while the survival rate had been decreased. Conclusion Endogenous CD4⁺CD25⁺Treg can provide obvious protection effect to the restraining the over immunity damage of the severe Klebsiella pneumonia for the mice.

Key words: CD4⁺CD25⁺Treg, Pneumonia, Sepsis, Klebsiella pneumoniae

苏鸿, 赵子文, 钟维农, 魏树全, 赵祝香, 梁志科, 方昌全. Treg在大鼠重症肺炎克雷伯菌肺炎中的调控作用[J]. 广州医药, 2015, 46(5): 1-4.

Su Hong, Zhao Ziwen, Zhong Weinong, et al. Role of Treg in the mouse severe Klebsiella pneumonia[J]. Guangzhou Medical Journal, 2015, 46(5): 1-4.

参考文献

[1] Chen K, Zhou QX, Shan HW,et al. Prognostic value of CD4(+)CD25(+) Tregs as a valuable biomarker for patients with sepsis in ICU[J].World J Emerg Med, 2015 (1):40-43.
[2] 卢伟波,赵子文,钟维农,等.肺炎克雷伯杆菌致大鼠重症肺炎模型的改良与评估[J]. 中国病理生理杂志,2013(3):571-576.
[3] Schulze B, Piehler D, Eschke M, et al. CD4(+) FoxP3(+) regulatory T cells suppress fatal T helper 2 cell immunity during pulmonary fungal infection[J]. Eur J Immunol,2014,44(12):3596-3604.
[4] Okeke EB, Okwor I, Mou Z,et al. CD4⁺CD25⁺ regulatory T cells attenuate lipopolysaccharide-induced systemic inflammatory responses and promotes survival in murine Escherichia coli infection[J]. Shock, 2013,40(1):65-73.
[5] 李辉,牛铭钢,金玮,等.外阴硬化苔藓患者HLA-DR抗原的表达及T细胞亚群变化的研究[J]. 哈尔滨医药:2010(1):1-4.
[6] Svetlana OC,Yong J Y,Thomas I, et al. Depletion of natural CD4⁺CD25⁺T regulatory cells with anti-CD25 antibody does not change the course of Pseudomonas aeruginosa-induced acute lung infection in mice[J]. Immunobiology,2009,214(3):211-222.
[7] Raghavan S, Quiding-Järbrink M.et al. Immune modulation by regulatory T cells in Helicobacter pylori-associated diseases[J]. Endocr Metab Immune Disord Drug Targets,2012 12(1):71-85.
[8] Siqueira-Batista R, Gomes AP, Azevedo SF, et al. CD4⁺CD25⁺ T lymphocytes and regulation of the immune system: perspectives for a pathophysiological understanding of sepsis[J]. Rev Bras Ter Intensiva,2012,24(3):294-301.
[9] Nguyen TL, Makhlouf NT, Anthony BA, et al. In vitro induced regulatory T cells are unique from endogenous regulatory T cells and effective at suppressing late stages of ongoing autoimmunity[J]. PLoS One,2014,9(8):e104698.
[10] Chen T, Jin R, Huang Z, et al. The variation of expression of CD4⁺ CD25⁺ Foxp3+ regulatory T cells in patients with Helicobacter pylori infection and eradication[J]. Hepatogastroenterology,2014,61(130):507-511.

[1]	卢延发. 序贯器官衰竭评分联合可溶性程序性死亡因子-1对脓毒症患者的预后的影响[J]. 广州医药, 2021, 52(6): 87-89.
[2]	张晓, 刘学星, 魏跃红. 广州市一起无症状感染者传播的家庭聚集性疫情特征和临床治疗分析[J]. 广州医药, 2021, 52(4): 35-39.
[3]	毛玉巧, 付喜花. 71例肝脓肿临床及病原学特点分析[J]. 广州医药, 2021, 52(4): 55-59.
[4]	董云玲, 张风林, 李永兵, 郭瑞娟. 某院209株肺炎克雷伯菌临床分布和耐药性分析[J]. 广州医药, 2021, 52(4): 86-91.
[5]	彭莎, 吴光雄, 刘文华. 血常规、血沉、C-反应蛋白水平对小儿急性肺炎的诊断价值分析[J]. 广州医药, 2021, 52(3): 68-70.
[6]	黄绮文, 孙小玲, 刘静娴. 家庭医生契约式服务对婴儿生长发育及肺炎发生率影响的研究[J]. 广州医药, 2021, 52(1): 35-38.
[7]	谭少娟, 吁英, 朱颖洁, 赵井阳, 杨富英, 萧蕊英. 临床护士对新型冠状病毒肺炎的知信行现状调查分析[J]. 广州医药, 2021, 52(1): 72-76.
[8]	司徒宝珠. MP-SAT作为支原体肺炎患儿疗效监测指标的可行性分析[J]. 广州医药, 2021, 52(1): 87-91.
[9]	黄育涛, 蔡幸生, 朱勇斌. 肺炎支原体RNA-SAT对儿童社区获得性肺炎诊治的价值[J]. 广州医药, 2020, 51(6): 94-97.
[10]	于磊, 钟小兰, 曹天生. 某新冠肺炎定点医院疫情期间病历管理方案的探索[J]. 广州医药, 2020, 51(6): 109-112.
[11]	李晓岩, 艾菊, 耿成亮, 刘明琦. 毕节地区新型冠状病毒肺炎胸部CT影像学特征[J]. 广州医药, 2020, 51(4): 75-79.
[12]	言佳锋, 魏新华, 林竹, 李丽琪. 防控COVID-19临时隔离病区的建立和影像检查优化运用[J]. 广州医药, 2020, 51(2): 5-9.
[13]	关则想, 李红, 白婷, 麦益友. 喘憋性肺炎合并患儿血清PCT、CRP水平观察[J]. 广州医药, 2020, 51(2): 106-109.
[14]	方昌全, 林俊鸿, 李裕军, 魏树全, 赵祝香, 李晓岩, 钟维农, 赵子文. CURB-65、PSI、SMART-COP及APACHEⅡ评分在重症社区获得性肺炎患者早期诊断价值的比较[J]. 广州医药, 2018, 49(5): 9-12.
[15]	谢叶红. 2012年—2016年我院肺炎链球菌的临床分布和耐药分析[J]. 广州医药, 2018, 49(1): 65-68.

Treg在大鼠重症肺炎克雷伯菌肺炎中的调控作用

Role of Treg in the mouse severe Klebsiella pneumonia

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价